Indefinite Delivery Contract 75D30125D20481
Award Date
7/1/25
Last Date to Order
6/30/26
Federal Agency
CDC Pittsburgh
Awardee
Moderna US, Inc.
Ultimate Awardee
Modernatx, Inc.
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Moderna US, Inc. to provide adult COVID-19 vaccines. The contract has a ceiling value of $19,855,000 and a period of performance from June 1, 2025 to May 31, 2026. Moderna US, Inc. is a subsidiary of the parent company Modernatx, Inc., both of which are for-profit organizations specializing in the manufacture of pharmaceutical goods, including mRNA therapeutics and vaccines. Under...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Moderna US, Inc. to provide pediatric COVID-19 vaccines. The contract has a ceiling value of $153,890,500 and a period of performance ending on May 31, 2026. Moderna US, Inc., a subsidiary of Modernatx, Inc., is a biotechnology company that specializes in developing and manufacturing mRNA therapeutics and vaccines. The company has received multiple federal contract awards to supply...
The federal contract IDV award is for the procurement of COVID-19 mRNA vaccines from Moderna US, Inc., a subsidiary of Modernatx, Inc. The Centers for Disease Control and Prevention (CDC), a civilian agency, awarded this multiple award indefinite delivery contract with a ceiling value of $117,420,333 and a period of performance through September 30, 2025. The contract builds upon previous COVID-19 vaccine procurements by the Biomedical Advanced Research and Development Authority and the...
The Centers for Disease Control and Prevention (CDC), a civilian federal agency, awarded a multiple award indefinite delivery contract to Moderna US, Inc. to provide adult COVID-19 vaccines. The contract has a ceiling value of $408,050,000 and a period of performance ending June 6, 2024. The contract was awarded without any set-aside designations. Under this IDIQ contract, Moderna will deliver standard commercial COVID-19 vaccines with an adult indication (age 19 and older) to the CDC's...
This federal contract IDV award was issued by the Centers for Disease Control and Prevention (CDC) to Moderna US, Inc. to provide COVID-19 pediatric vaccines. The multiple-award IDV has a total ceiling value of $240,548,000 and a period of performance ending on September 30, 2025. Moderna US, Inc. is the prime contractor for this award, which was not set aside for any specific socioeconomic category. The contract aims to procure COVID-19 pediatric vaccines to support the CDC's preparedness and...
This federal contract IDV award from the Centers for Disease Control and Prevention (CDC) is for the procurement of standard commercial COVID-19 vaccines with a pediatric indication for children ages 0 through 18 years. The contract is a multiple award, indefinite delivery indefinite quantity (IDIQ) vehicle, with a ceiling value of $601,370,000 and a period of performance ending June 6, 2024. The prime contractor is Moderna US, Inc., a biotechnology company that develops and manufactures mRNA...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Novavax Inc. to provide adult COVID-19 vaccines. The contract has a ceiling value of $13,961,250 and a period of performance through May 31, 2025. As a prime contractor, Novavax will deliver COVID-19 vaccine products and services out of its Maryland facility to support the CDC's public health response. Novavax is an experienced federal contractor, having previously received a $45.7...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Novavax Inc., a biotechnology company that develops and produces recombinant protein nanoparticle vaccines. The $116 million contract is to provide pediatric COVID-19 vaccines if regulatory approval is obtained. The IDC is a multiple award vehicle, meaning there are multiple contractors that can compete for individual task orders. The period of performance runs through June 6, 2024....
The key points from the provided information are as follows: This is an Indefinite Delivery Contract (IDC) awarded by the Centers for Disease Control and Prevention (CDC) to the prime contractor Merck Sharp & Dohme LLC, doing business as Merck, a major pharmaceutical manufacturer. The contract has a ceiling value of $86,407,050 and a period of performance from July 1, 2019 to June 30, 2020. The purpose of this IDC is to provide a wide range of vaccines for adults, including MMR, varicella,...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian federal agency, to Pfizer Inc., a large pharmaceutical manufacturer, on June 1, 2025. The $458,750,000 multiple-award contract has an ultimate completion date of May 31, 2026 and is for the procurement of adult COVID-19 vaccines. As a prime contractor, Pfizer will be responsible for supplying the CDC's Pittsburgh location with the necessary COVID-19 vaccine products over the...